Eli Lilly to Acquire Orna Therapeutics in Deal Valued at Up to $2.4 Billion
Global pharmaceutical major Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, a biotechnology firm focused on engineering immune cells directly inside the human body. The acquisition marks a significant move by Lilly to expand its capabilities in next-generation genetic medicines and in vivo cell therapies. Under the terms of … Read more